|
Originally published In Press as doi:10.1074/jbc.M506147200 on August 23, 2005
J. Biol. Chem., Vol. 280, Issue 43, 36355-36363, October 28, 2005
Modulation of Androgen Receptor Transactivation by FoxH1
A NEWLY IDENTIFIED ANDROGEN RECEPTOR COREPRESSOR*
Guangchun Chen 1,
Masatoshi Nomura 2,
Hidetaka Morinaga ,
Eri Matsubara ,
Taijiro Okabe ,
Kiminobu Goto ,
Toshihiko Yanase ,
Hong Zheng¶,
Jian Lu , and
Hajime Nawata
From the
Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan and Department of Pathophysiology and ¶Laboratory Center of Pharmacology, Second Military Medical University, 800, Xiang Yin Road, Shanghai 200433, China
Androgen signaling plays key roles in the development and progression of prostate cancer, and numerous ongoing studies focus on the regulation of androgen receptor (AR) transactivity to develop novel therapies for the treatment of androgen-independent prostate cancer. FoxH1, a member of the Forkhead-box (FOX) gene family of transcription factors, takes part in mediating transforming growth factor- /activin signaling through its interaction with the Smad2·Smad4 complex. Using a series of experiments, we found that FoxH1 repressed both ligand-dependent and -independent transactivation of the AR on androgen-induced promoters. This action of FoxH1 was independent of its transactivation capacity and activin A but relieved by Smad2·Smad4. In addition, the repression of the AR by FoxH1 did not require deacetylase activity. A protein-protein interaction was identified between the AR and FoxH1 independently of dihydrotestosterone. Furthermore, a confocal microscopic analysis of LNCaP cells revealed that the interaction between the AR and FoxH1 occurred in the nucleus and that FoxH1 specifically blocked the foci formation of dihydrotestosterone-activated AR, which has been shown to be correlated with the AR transactivation potential. Taken together, our results indicate that FoxH1 functions as a new corepressor of the AR. Our observations not only strengthen the role of FoxH1 in AR-mediated transactivation but also suggest that therapeutic interventions based on AR-coregulator interactions could be designed to block both androgen-dependent and -independent growth of prostate cancer.
Received for publication, June 6, 2005
, and in revised form, August 11, 2005.
* This work was supported in part by a grant-in-aid for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported in part by a Sasakawa Medical Grant from the Japan-China Medical Association.
2 To whom correspondence should be addressed. Tel.: 81-92-642-5280; Fax: 81-92-642-5297; E-mail: nomura{at}med.kyushu-u.ac.jp.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
H. V. Heemers and D. J. Tindall
Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex
Endocr. Rev.,
December 1, 2007;
28(7):
778 - 808.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Santos, V. L. Workman, G. C. Paull, A. L. Filby, K. J. W. Van Look, P. Kille, and C. R. Tyler
Molecular basis of sex and reproductive status in breeding zebrafish
Physiol Genomics,
July 18, 2007;
30(2):
111 - 122.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Valentini, M. Biancolella, F. Amati, P. Gravina, R. Miano, G. Chillemi, A. Farcomeni, S. Bueno, G. Vespasiani, A. Desideri, et al.
Valproic Acid Induces Neuroendocrine Differentiation and UGT2B7 Up-Regulation in Human Prostate Carcinoma Cell Line
Drug Metab. Dispos.,
June 1, 2007;
35(6):
968 - 972.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Fan, T. Yanase, H. Morinaga, T. Okabe, M. Nomura, H. Daitoku, A. Fukamizu, S. Kato, R. Takayanagi, and H. Nawata
Insulin-like Growth Factor 1/Insulin Signaling Activates Androgen Signaling through Direct Interactions of Foxo1 with Androgen Receptor
J. Biol. Chem.,
March 9, 2007;
282(10):
7329 - 7338.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J Burd, L. M Morey, and K. E Knudsen
Androgen receptor corepressors and prostate cancer
Endocr. Relat. Cancer,
December 1, 2006;
13(4):
979 - 994.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|